Takeda announces publication of data from solstice, a pivotal phase 3 trial for livtencity™ (maribavir) in post-transplant recipients with cytomegalovirus (cmv) infection (refractory, with or without resistance)

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that the data from the pivotal phase 3 solstice clinical trial of livtencity™ (maribavir, tak-620) in post-transplant refractory† cmv infections with or without resistance‡ (r/r) were published in the journal of clinical infectious diseases (cid). the manuscript is available online and will be included in a future print edition of cid, the official peer-reviewed
TAK Ratings Summary
TAK Quant Ranking